Gilead Sciences is paying tiny Tango Therapeutics $50 million to tap into the startup’s cancer drug program, adding to what has been so far an expensive, but not yet lucrative, foray into cancer immunotherapy for Gilead.
Cambridge, MA-based Tango is still in the early phases of looking for cancer drugs by exploiting a well-known tumor vulnerability, known as synthetic lethality, in a very modern way: gene editing. Gilead could potentially combine Tango’s drugs with an established kind of immunotherapy called checkpoint inhibitors, said Tango CEO and president Barbara Weber.
It is unclear if Foster City, CA-based Gilead (NASDAQ: GILD) plans… Read more »
UNDERWRITERS AND PARTNERS